Abstract
American Journal of Biomedical Science & Research provides a unique platform where you can share the original research in supporting the advancement of Science, Technology, Engineering & Medicine and biomedical sciences journals
Highlights
In recent years, immunotherapy has led to a paradigm shift in lung cancer treatment, as in several other solid tumors, for which immune checkpoint inhibitors (ICIs) are the most widely applied in research and clinical trials
Therapeutic efficacy was evaluated as a partial response. In this case of stage IIIB lung adenocarcinoma where chemotherapy failed, concurrent immunoradiotherapy followed by consolidation camrelizumab therapy led to a successful response, with an encouraging clinical outcome
This report provides clinicians with a possible alternative strategy for the treatment of locally advanced non-small cell lung cancer (NSCLC) that does not respond to chemotherapy
Summary
We present a case of stage IIIB lung adenocarcinoma in which chemotherapy failed. Concurrent immunotherapy led to a successful response, and the clinical outcomes were encouraging. This case provides clinicians with an alternative strategy for the treatment of locally advanced NSCLC that does not respond to chemotherapy. We anticipate further optimization of multiple treatment strategies that can yield better survival benefits to patients with lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
